Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 5/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 4/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 2/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15058190 | 0.81 | TRPA1 (0.41) | PDE3BPDE3ATRPA1DRD1PRKCI | |
| SCHEMBL31409617 | 0.81 | TRPA1 (0.45) | PDE3BPDE3ATRPA1DRD1NUDT1 | |
| SCHEMBL18584885 | 0.81 | PDE3B (0.57) | PDE3BPDE3ATRPA1DRD1NUDT1 | |
| Hydrochloric Acid SCHEMBL30647259 | 0.79 | PDE3B (0.56) | PDE3BPDE3ATRPA1DRD1NUDT1 | |
| SCHEMBL18238493 | 0.75 | PDE3B (0.47) | PDE3BPDE3A | |
| SCHEMBL14062157 | 0.74 | NUDT1 (0.40) | PDE3BPDE3ATRPA1DRD1NUDT1 | |
| SCHEMBL4550230 | 0.74 | PDE3B (0.58) | PDE3BPDE3ATRPA1DRD1PRKCI | |
| SCHEMBL10810746 | 0.73 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL18238030 | 0.72 | PDE3B (0.51) | PDE3BPDE3ADRD1AXL | |
| SCHEMBL21388648 | 0.72 | PDE3B (0.33) | PDE3BPDE3ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | PDE3B 4632/4885PDE3A 4690/4885TRPA1 4214/4885 |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | PDE3B 4711/4885PDE3A 4737/4885TRPA1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.